Colitis: Clinical Trials

32 trials for Colitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 terminated. 32 Phase 3, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 332Terminated 32
Phase 210Terminated 10

Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio
AVT16, Vedolizumab - Ulcerative Colitis
Phase 3TerminatedAlvotech Swiss AG3012024-09-232025-12-26
A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Ozanimod, Placebo - Ulcerative Colitis
Phase 3TerminatedBristol-Myers Squibb1312022-12-092025-03-26
A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
Filgotinib, Placebo - Ulcerative Colitis
Phase 3TerminatedLakefront Biotherapeutics NV222022-07-262024-10-04
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo - Ulcerative Colitis
Phase 3TerminatedInDex Pharmaceuticals1712021-11-242023-12-27
Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
Valganciclovir - Ulcerative Colitis, Unspecified
Phase 3TerminatedCentre Hospitalier Universitaire de Saint Etienne62021-04-222024-04-10
Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis
Rosuvastatin 10mg - Ulcerative Colitis
Phase 2 / Phase 3TerminatedUniversitaire Ziekenhuizen KU Leuven1772020-10-222025-11-25
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C - Ulcerative Colitis (UC)
Phase 2 / Phase 3TerminatedTheravance Biopharma462020-07-232022-11-02
The Role of Secondary Bile Acids in Intestinal Inflammation
ursodiol (ursodeoxycholic acid, UDCA) - Ulcerative Colitis, Pouchitis
Phase 2 / Phase 3TerminatedStanford University22019-08-262026-03-11
Efficacy & Safety of TD-1473 in Ulcerative Colitis
TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C - Ulcerative Colitis (UC)
Phase 2 / Phase 3TerminatedTheravance Biopharma2392019-03-112022-11-15
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
Ontamalimab, Placebo - Ulcerative Colitis
Phase 3TerminatedShire3802018-02-092021-06-14
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
Ontamalimab, Placebo - Ulcerative Colitis
Phase 3TerminatedShire2792017-12-052021-04-26
Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC
Tacrolimus, Vedolizumab, Placebo - Ulcerative Colitis
Phase 3TerminatedMedical College of Wisconsin42017-05-182020-09-03
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
LT-02, LT-02 Placebo - Ulcerative Colitis
Phase 3TerminatedPrometheus Laboratories252016-07-012017-06-15
Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis
Andecaliximab, Placebo - Ulcerative Colitis
Phase 2 / Phase 3TerminatedGilead Sciences1652015-09-012019-04-10
Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study
Loperamide, Placebo - Rectal Cancer, Ulcerative Colitis
Phase 3TerminatedOdense University Hospital122014-10-012016-10-11
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
Etrolizumab - Ulcerative Colitis
Phase 3TerminatedHoffmann-La Roche18222014-09-152024-10-23
Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis
LT-02, Placebo - Ulcerative Colitis
Phase 3TerminatedDr. Falk Pharma GmbH4682014-07-212017-02-09
Hyperbaric Oxygen for Ulcerative Colitis
Hyperbaric oxygen, Sham Hyperbaric Air - Ulcerative Colitis
Phase 2 / Phase 3TerminatedDartmouth-Hitchcock Medical Center182013-08-012018-04-06
HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
HMPL-004, Placebo - Ulcerative Colitis
Phase 3TerminatedHutchison Medipharma Limited662013-06-012020-01-13
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
HMPL-004 1800 mg/day, Placebo, HMPL-004 2400 mg/day - Ulcerative Colitis
Phase 3TerminatedHutchison Medipharma Limited2012013-03-012020-01-02

Showing 20 of 32. Sign in to see all of them.

Narrower conditions

Colitis, Ulcerative (30)  ·  Inflammatory Bowel Diseases (7)  ·  Gastrointestinal Diseases (4)  ·  Colonic Diseases (3)  ·  Ulcer (3)  ·  Digestive System Diseases (2)  ·  Gastroenteritis (2)  ·  Intestinal Diseases (2)  ·  Pathologic Processes (2)  ·  Proctitis (2)  ·  Proctocolitis (2)  ·  Colitis, Lymphocytic (1)  ·  Crohn Disease (1)  ·  Cytomegalovirus Infections (1)

Broader conditions

Digestive System Diseases (30)  ·  Gastroenteritis (30)  ·  Intestinal Diseases (30)  ·  Colonic Diseases (29)  ·  Gastrointestinal Diseases (28)  ·  Inflammatory Bowel Diseases (24)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Pathologic Processes (3)  ·  Neoplasms (2)  ·  Rectal Diseases (2)  ·  Behavior (1)  ·  Colitis, Microscopic (1)  ·  Colorectal Neoplasms (1)  ·  DNA Virus Infections (1)

Interventions

Mesalamine (3)  ·  Andrographis paniculata extract (2)  ·  Azathioprine (2)  ·  Infliximab (2)  ·  Valganciclovir (2)  ·  ontamalimab (2)  ·  vedolizumab (2)  ·  visilizumab (2)  ·  Budesonide (1)  ·  GLPG0634 (1)  ·  Hyperbaric Oxygenation (1)  ·  Loperamide (1)  ·  Prednisolone (1)  ·  Prednisone (1)  ·  Rosuvastatin Calcium (1)

Sponsors

Facet Biotech (2)  ·  Hutchison Medipharma Limited (2)  ·  Merck Sharp & Dohme LLC (2)  ·  Shire (2)  ·  Theravance Biopharma (2)  ·  sigma-tau i.f.r. S.p.A. (2)  ·  Alvotech Swiss AG (1)  ·  Bausch Health Americas, Inc. (1)  ·  Bristol-Myers Squibb (1)  ·  Centre Hospitalier Universitaire de Saint Etienne (1)  ·  Dartmouth-Hitchcock Medical Center (1)  ·  Dr. Falk Pharma GmbH (1)  ·  Forest Laboratories (1)  ·  Gilead Sciences (1)  ·  Hoffmann-La Roche (1)

Countries

United States (21)  ·  France (12)  ·  Poland (12)  ·  Canada (11)  ·  Germany (11)  ·  Hungary (11)  ·  Belgium (10)  ·  Romania (10)  ·  Slovakia (10)  ·  Australia (9)  ·  Israel (9)  ·  Italy (9)  ·  Ukraine (9)  ·  Netherlands (8)  ·  Austria (7)

Top investigators

Sandro Ardizzone, MD (2)  ·  Andres J Yarur, MD (1)  ·  Axel Dignass, MD (1)  ·  Corey A Siegel, MD, MS (1)  ·  Darrell S. Pardi, M.D. (1)  ·  Eveline Schurink (1)  ·  Gregory Gordon, M.D., J.D. (1)  ·  Herman Ellman, MD (1)

Results publications

PMID 40013523, PMID 20947884, PMID 24512909, PMID 26119226, PMID 28627732, PMID 31982148, PMID 32445184, PMID 37806372

NIH funding

2017 (2), 2018 (2), 2009 (1), 2014 (1), 2016 (1), 2019 (1), UL1RR024150 (1)